Ankit Panthari: Can Haemophilia Serve as A Health System Model for Other Rare Diseases in India?
Ankit Panthari, Former Business Unit Head, Plasma Derived Therapies at Takeda, shared on LinkedIn:
”Had the opportunity to participate in a thought provoking panel discussion at the National Hemophilia Conclave 2026 on an important question: Can haemophilia serve as a health system model for other rare diseases in India?
Haemophilia, despite its continuing challenges and gaps is perhaps one of India’s most evolved examples of how patient advocacy, physician leadership, policy evolution, diagnostics, procurement systems and comprehensive care models can come together to create meaningful progress in rare diseases.
Over the years, Indian haemophilia care has evolved from transfusion based support to plasma derived factors, recombinant therapies, and now non- factor treatments.
Treatment centres have expanded from a few dozen to nearly 400 nationwide.
Diagnosis rates have steadily improved and are now estimated at approximately 18–20%, while prophylaxis adoption is gradually increasing and estimated at around approximately 10%.
What makes the broader rare disease landscape far more challenging is its heterogeneity and complexity.
With more than 10,000 recognized rare diseases globally, conditions differ widely in symptoms, diagnostics, treatment availability, access pathways, and long term outcomes.
Scientifically approved therapies exist for only a minority of diseases.
Even India’s ICMR registry (NRROID), with approximately 16,000 registered patients likely represents only a fraction of the true burden, highlighting the continuing challenges of diagnosis, data capture, registries, and genomic access.
Haemophilia is not a ‘cut copy paste’ model, but a strong operational reference point from which tailored and scalable rare disease ecosystems can evolve.
It was a privilege to exchange perspectives with fellow distinguished panelists and experts from across the rare disease ecosystem.
A special thanks to Dr Naresh Gupta and the Hemophilia Health Collective of North (HHCN) team for curating such a meaningful and forward looking discussion.”
Stay updated with Hemostasis Today.
-
Jul 13, 2026, 23:39Yaariv Khaykin: Whole-Person Care Can Strengthen Stroke Prevention in Patients With Atrial Fibrillation
-
Jul 13, 2026, 22:33ESOC 2026 recordings are now available on eSTEP – European Stroke Organisation
-
Jul 13, 2026, 20:17Julia R. Coleman: Fantastic First Day at ISTH 2026
-
Jul 13, 2026, 20:11Ruah Alyamany: Combination Therapy Improves Quality of Life in ITP
-
Jul 13, 2026, 19:47Brian O Mahony: Two-Year Results of BBM-H901 Gene Therapy Presented at ISTH 2026
-
Jul 13, 2026, 19:37Sara Zalghout: Connecting With Colleagues From All Over the World at ISTH 2026
-
Jul 13, 2026, 18:54Alfonso J. Tafur: New Evidence on Perioperative Anticoagulation in Cancer at ISTH 2026
-
Jul 13, 2026, 18:42Jessica Garcia: Thrombin Generation in Type 3 VWD With an Inhibitor on Emicizumab
-
Jul 13, 2026, 18:19Fionnuala Ní Áinle: High-Quality Evidence for DVT Diagnosis in Pregnancy at ISTH 2026